title: A simplified pharmacologic erection program for patients with spinal cord injury.
abstract: OBJECTIVE
  Intracavernosal injection (ICI) of vasoactive agents has been successfully used in the treatment of erectile dysfunction (ED). The authors' pharmacologic erection program, using a fixed combination of prostaglandin E1 (PGE1) and papaverine, is notable for its simplicity and acceptance by patients who have suffered spinal cord injuries (SCIs).
  
  
  METHODS
  Patients undergo baseline questionnaire, physical examination, and hormone profile followed by instruction and injection of a fixed combination of PGE1 and papaverine. On successive visits, the patient injects himself and the dosage is titrated until a satisfactory erection is obtained. Patients who do not respond to injection of 1.0 cc are considered treatment failures. Patients return periodically for routine follow-up.
  
  
  RESULTS
  From May 1994 to March 1997, 37 patients with SCI underwent initial evaluation and 28 (76%) responded to injection therapy and were successfully using self-injection therapy at 3-month follow-up. Twenty-three patients are still on injection therapy. Five patients have dropped out for several reasons including a lack of a current sexual partner (60%) and pain with injection (40%). Patient age ranges from 24 to 72. The dosage range was 0.10 to 0.50 cc (mean = 0.29 cc). The average duration of erection was 43 minutes. At 3-month follow-up, 85% of the patients rated their erections as good or excellent. Forty-three percent of patients are using ICI 1 or more times per week. Seventy-seven percent of patients are moderately or extremely satisfied with their treatment and 89% said that they would recommend this program to a friend.
  
  
  CONCLUSIONS
  This simplified pharmacologic erection program offers safe, well accepted, and effective therapy for ED to a SCI population with very high patient satisfaction.
authors.affiliation: Department of Urology, Mount Sinai School of Medicine, New York, New York, USA.
authors.forename: S
authors.initials: S
authors.lastname: Zaslau
authors.forename: C
authors.initials: C
authors.lastname: Nicolis
authors.forename: G
authors.initials: G
authors.lastname: Galea
authors.forename: J
authors.initials: J
authors.lastname: Britanico
authors.forename: J M
authors.initials: JM
authors.lastname: Vapnek
mesh_terms: D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage*; D007172:Erectile Dysfunction / Q000534:rehabilitation*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage*; D017060:Patient Satisfaction; D010410:Penile Erection / Q000187:drug effects*; D013119:Spinal Cord Injuries / Q000534:rehabilitation*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D014665:Vasodilator Agents; D010208:Papaverine; D000527:Alprostadil